CVKD news

Cadrenal Therapeutics (CVKD) has retained Tungsten Advisors to lead a formal evaluation of strategic alternatives, including potential partnerships and asset sales, as its pipeline matures following FDA alignment on CAD-1005. This development highlights the Company's proactive approach to maximizing…

Cadrenal Therapeutics announced FDA alignment on the primary endpoint and trial design for CAD-1005, a first-in-class therapy for heparin-induced thrombocytopenia. The agreement positions the company to advance its phase 3 registrational study for this high-value condition.

Cadrenal announced a strategic partnering process for its cardiology assets following positive Phase 2 data presentation and reorganization of its portfolio into a dedicated franchise.

Cadrenal Therapeutics announced plans to submit a Rare Pediatric Disease Designation request to the FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms. Approval could qualify the company for a Priority Review Voucher valued around $200 million, providing s…